# A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment

> **NCT02864199** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 63 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Peginterferon alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02864199
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2016-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02864199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02864199, "A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02864199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*